公开(公告)号：US20200155676A1

公开(公告)日：2020-05-21

申请号：US16453650

申请日：2019-06-26

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Yuanyuan XIAO ,  Patrick CAPLAZI ,  Steve LIANOGLOU ,  Jason HACKNEY ,  Eugene Yu-Chuan CHIANG

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/24 ,  A61K47/62 ,  C07K16/30

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.

公开(公告)号：US20170226198A1

公开(公告)日：2017-08-10

申请号：US15581448

申请日：2017-04-28

Applicant: Genentech, Inc.

Inventor： Yuanyuan XIAO ,  Carlos BAIS ,  YounJeong CHOI ,  Nicola C. CONSALVO

IPC: C07K16/22 ,  A61K39/395 ,  G01N33/574 ,  A61K31/495 ,  A61K38/21 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/22 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/57449 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2800/52 ,  A61K2300/00

Abstract: The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.

公开(公告)号：US20170274073A1

公开(公告)日：2017-09-28

申请号：US15448437

申请日：2017-03-02

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Yuanyuan XIAO ,  Patrick CAPLAZI ,  Steve LIANOGLOU ,  Jason HACKNEY ,  Eugene Yu-Chuan CHIANG

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/28

CPC classification number: A61K39/39558 ,  A61K47/62 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2300/00 ,  C07K16/244 ,  C07K16/2827 ,  C07K16/3053 ,  C07K2317/33

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.